2. Signaling Pathways
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras

Ras

Ras

Related Products

PDF 2.6 MB

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

Ras Isoform Specific Products:

Ras Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-180298
    KRAS G12C-IN-71
    		Inhibitor
    KRAS G12C-IN-71 (Compound 11) is a covalent G12C KRAS inhibitor with a Ki of 380 nM. KRAS G12C-IN-71 can be used in the research of non-small cell lung cancer.
    KRAS G12C-IN-71
  • HY-174851
    KRAS G12C-IN-70
    		Inhibitor
    KRAS G12C-IN-70 is a selective KRAS G12C mutant inhibitor. KRAS G12C-IN-70 blocks KRAS G12C-mediated downstream signaling pathways (e.g., RAF-MEK-ERK) and inhibits tumor cell proliferation. KRAS G12C-IN-70 is promising for research of KRAS G12C mutation-related tumors (such as non-small cell lung cancer, colorectal cancer).
    KRAS G12C-IN-70
  • HY-183365
    SL43
    		Inhibitor
    SL43 is an orally active and potent SOS1 inhibitor with a Kd of 0.16 μM. SL43 disrupts SOS1-KRAS interaction, inhibits SOS1-mediated nucleotide exchange on KRAS mutants, and suppresses RAS-MAPK signaling. SL43 exerts antiproliferative activity against KRAS-mutant cancer cells, induces early apoptosis and G1 phase cell cycle arrest, and reduces phosphorylated MEK and ERK levels. SL43 suppresses tumor growth in a colorectal cancer xenograft model.
    SL43
  • HY-178042
    SS-3091
    		Inhibitor
    SS-3091 is a pan-KRas inhibitor active across KRasG12D, KRasG12C, KRasG12V, KRasG12S mutants, with minimal effects on non-KRas-driven cancer cells. SS-3091 binds to the KRas·ARaf interaction interface, destabilizes the complex, and attenuates KRas activity. SS-3091 suppresses phosphorylation of S6K, Akt, and ERK. SS-3091 reduces proliferation and decreases colony formation of cancer cells bearing KRasG12 mutations. SS-3091 can be used for the research of KRas-driven cancers.
    SS-3091
  • HY-117893
    BIM-46068
    		Inhibitor
    BIM-46068 is a potent, selectively human brain Farnesyltransferase (FTase) inhibitor (IC50 = 91.4 nM). BIM-46068 can specifically inhibit Ras processing in MiaPaCa-2 cancer cells. BIM-46068 can be used for the study of pancreatic cancer.
    BIM-46068
  • HY-146475
    KRAS inhibitor-17
    		Inhibitor
    KRAS inhibitor-17 (compound 3-9) is a potent KRAS G12C inhibitor with an IC50 of 3.37 µM. KRAS inhibitor-17 shows p-ERK inhibition activities with IC50s of 9.25, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-17 has the potential for the research of pancreatic, colorectal, and lung cancers.
    KRAS inhibitor-17
  • HY-182749
    KRAS-IN-58
    		Inhibitor
    KRAS-IN-58 is a KRAS inhibitor with a IC50 of 0.223 μM against KRASG12D. KRAS-IN-58 binds to KRASG12C and KRASG12D proteins, and reduces the levels of phosphorylated Raf1, AKT and ERK in pancreatic cancer cells. KRAS-IN-58 can be used for the research of pancreatic cancer.
    KRAS-IN-58
  • HY-170647
    SEPT9-IN-1
    SEPT9-IN-1 (compound 8b) is a SEPT9 inhibitor with an IC50 value of 94.83 μM. SEPT9-IN-1 shows cytotoxicity to human oral squamous carcinomas with an IC50 value of 21 µM.
    SEPT9-IN-1
  • HY-113680
    KY1022
    		Degrader
    KY1022 is a small molecule destabilizing Ras via targeting the Wnt/β-catenin pathway. KY1022 can inhibit cellular EMT, metastasis and apoptosis. KY1022 can be used for the research of metastatic colorectal cancer.
    KY1022
  • HY-118692
    DCAI
    		Inhibitor
    DCAI is Ras protein binder. DCAI can inhibit the Ras activation and nucleotide exchange mediated by SOS. DCAI can be used for the research of cancer associated with Ras mutations .
    DCAI
  • HY-163334
    GGDPS-IN-1
    		Inhibitor
    GGDPS-IN-1 (Compound 37) is a geranylgeranyl diphosphate synthase (GGDPS) inhibitor with an IC50 of 49.4 nM. GGDPS-IN-1 disrupts protein geranylgeranylation in myeloma cells.
    GGDPS-IN-1
  • HY-W174279
    Tyrphostin 8
    		Inhibitor 98.0%
    Tyrphostin 8 is a tyrosine kinase, with an IC50 of 560 μM for EGFR kinase. Tyrphostin 8 is also a GTPase inhibitor. Tyrphostin 8 can inhibit the protein serine/threonine phosphatase calcineurin (IC50=21 μM).
    Tyrphostin 8
  • HY-144210
    SOS1-IN-6
    		Inhibitor
    SOS1-IN-6 (compound 33-P1) is a potent SOS1 inhibitor with IC50s of 14.9 and 73.3 nM for SOS1-G12D and SOS1-G12V, respectively.
    SOS1-IN-6
  • HY-P991156
    Rapaprutug
    		Ligand
    Rapaprutug is a monoclonal antibody targeting human KARS1 (lysyl-tRNA synthetase 1). Rapaprutug blocks the relevant inflammatory signaling pathways in which KARS1 is involved, reducing the production and release of inflammatory factors. Rapaprutug is promising for research of inflammatory diseases.
    Rapaprutug
  • HY-171581
    KRAS G12D-IN-27
    		Inhibitor
    KRAS G12D-IN-27 (H12a) is an inhibitor of KRAS G12D. KRAS G12D-IN-27 inhibits ERK phosphorylation, with an IC50 of 112 nM. KRAS G12D-IN-27 can be used in cancer research.
    KRAS G12D-IN-27
  • HY-181965
    KRAS G12C-IN-78
    		Inhibitor
    KRAS G12C-IN-78 is a selective SWII-binding KRASG12C dual inhibitor targeting both inactive and active states. KRAS G12C-IN-78 rapidly inhibits ERK1/2 phosphorylation, induces covalent adduct formation with endogenous KRASG12C, suppresses MAPK pathway gene expression, and inhibits cellular proliferation in KRASG12C mutant cells. KRAS G12C-IN-78 can be used for the research of KRASG12C mutant solid tumors, including pancreatic ductal adenocarcinoma and non-small cell lung cancer.
    KRAS G12C-IN-78
  • HY-128553A
    (Rac)-Antineoplaston A10
    		Inhibitor 99.36%
    (rac)-Antineoplaston A10 is the racemate of Antineoplaston A10. Antineoplaston A10 is a Ras inhibitor potentially for the treatment of glioma, lymphoma, astrocytoma and breast cancer.
    (Rac)-Antineoplaston A10
  • HY-142947
    KRAS G12C inhibitor 45
    		Inhibitor
    KRAS G12C inhibitor 45 (compound 78) is a potent KRAS G12C inhibitor.
    KRAS G12C inhibitor 45
  • HY-112492
    KRas G12C inhibitor 2
    		Inhibitor
    KRas G12C inhibitor 2 is a compound that inhibits KRas G12C, extracted from patent US 20180072723 A1.
    KRas G12C inhibitor 2
  • HY-186198
    FTS-MOM
    		Inhibitor
    FTS-MOM (Salirasib methoxymethyl ester), a Salirasib (FTS) (HY-14754) derivative, is a selective Rap1 inhibitor with selectivity over Ras. FTS-MOM inhibits GTP loading of Rap1 in quiescent and activated T cells. FTS-MOM inhibits Rap1-dependent T cell adhesion to ICAM-1.
    FTS-MOM
Cat. No. Product Name / Synonyms Application Reactivity
Ras Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.